Product Name :
MKI-1
Description:
MKI-1, an inhibitor of MASTL (microtubule-associated serine/threonine kinase-like) with an IC50 of 9.9 μM, exerts antitumor and radiosensitizer activities through PP2A activation in breast cancer.
CAS:
1190277-80-5
Molecular Weight:
302.33
Formula:
C18H14N4O
Chemical Name:
N-(1H-1,3-benzodiazol-2-yl)-3-(1H-pyrrol-1-yl)benzamide
Smiles :
O=C(NC1NC2=CC=CC=C2N=1)C1=CC(=CC=C1)N1C=CC=C1
InChiKey:
XKDZPQAMBMLCDQ-UHFFFAOYSA-N
InChi :
InChI=1S/C18H14N4O/c23-17(21-18-19-15-8-1-2-9-16(15)20-18)13-6-5-7-14(12-13)22-10-3-4-11-22/h1-12H,(H2,19,20,21,23)
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Chloroquine} web|{Chloroquine} Autophagy|{Chloroquine} Protocol|{Chloroquine} In stock|{Chloroquine} manufacturer|{Chloroquine} Autophagy}
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
MKI-1, an inhibitor of MASTL (microtubule-associated serine/threonine kinase-like) with an IC50 of 9.9 μM, exerts antitumor and radiosensitizer activities through PP2A activation in breast cancer.|Product information|CAS Number: 1190277-80-5|Molecular Weight: 302.33|Formula: C18H14N4O|Chemical Name: N-(1H-1,3-benzodiazol-2-yl)-3-(1H-pyrrol-1-yl)benzamide|Smiles: O=C(NC1NC2=CC=CC=C2N=1)C1=CC(=CC=C1)N1C=CC=C1|InChiKey: XKDZPQAMBMLCDQ-UHFFFAOYSA-N|InChi: InChI=1S/C18H14N4O/c23-17(21-18-19-15-8-1-2-9-16(15)20-18)13-6-5-7-14(12-13)22-10-3-4-11-22/h1-12H,(H2,19,20,21,23)|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 250 mg/mL (826.91 mM; Need ultrasonic).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Loperamide} MedChemExpress|{Loperamide} GPCR/G Protein|{Loperamide} Biological Activity|{Loperamide} In Vivo|{Loperamide} supplier|{Loperamide} Epigenetics} |Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|MKI-1 (5-20 μM) inhibits the activity of MASTL in breast cancer cells.PMID:24635174 MKI-1 (100 μM, 72 h) inhibits various oncogenic properties of breast cancer cells but showed much weaker effects on the viability of normal breast cells. MKI-1 clearly reduces both serine 62-phosphorylation of c-Myc and total c-Myc, with a decrease in ENSA phosphorylation. MKI-1 (20 μM, 16 h) reduces c-Myc stability through PP2A activation in MCF7 cells.|In Vivo:|MKI-1 (50 mg/kg, ip, twice a week) reduces tumor growth and enhances the radiosensitivity of BT549 xenograft model in response to 6 Gy irradiation compared with the control group, with no notable changes in body weight, suggesting the absence of gross toxicity in the treated mice.|Products are for research use only. Not for human use.|
